阿德福韦酯联合柔肝化纤颗粒治疗慢性乙型肝炎肝硬化临床效果

Abstract
Figure/Table
References (26)
Related Citation (7)

Download: PDF (714 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical efficacy of Adefovir Dipivoxil combined with Rougan Huaxian Granules in the treatment of patients with chronic hepatitis B virus (HBV) cirrhosis. Methods From March 2017 to March 2019, 100 patients with chronic hepatitis B cirrhosis diagnosed by The First Affiliated Hospital of Guangxi University of Chinese Medicine were selected. According to the random number table method, they were divided into the control group and the treatment group, with 50 patients in each group. The control group was treated with Adefovir Dipivoxil alone, and the treatment group was treated with Rougan Huaxian Granules on the basis of the control group for a total of 6 months. The clinical symptoms, liver function, liver fibrosis 4 items, liver B-mode ultrasound, the content of HBV-DNA, hepatitis B e antigen (HBeAg) and hepatitis B e antibody (HBeAb) in the two groups were observed before and after treatment. Results The traditional Chinese medicine syndrome scores of patients in both groups after treatment were better than those before treatment, and the treatment group was better than the control group at the same period (P ＜ 0.05). In the two groups after treatment liver function index [aspartic transaminase (AST), alanine transaminase (ALT), total bilirubin (HBIL)], liver fibrosis index [serum hyaluronic acid (HA), laminin (LN), type Ⅲ procollagen (PCⅢ), type Ⅳ collagen (Ⅳ-C)], portal vein diameter, the thickness of the spleen decreased significantly before the treatment (all P ＜ 0.05), and compared with the control group, the degree of the treatment group decreased more significantly (P ＜ 0.05). After treatment, HBV-DNA negative conversion rate, HBeAg negative conversion rate and HBeAg/HBeAb serum conversion in the treatment group were all higher than those in the con

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LYU Yanhang1 WU Shanshan1 WANG Zhenchang2

Cite this article:

LYU Yanhang1 WU Shanshan1 WANG Zhenchang2. Clinical effect of Adefovir Dipivoxil combined with Rougan Huaxian Granules on chronic hepatitis B cirrhosis[J]. 中国医药导报, 2019, 16(32): 107-110.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I32/107

[1] Xiao J，Wang F，Wong NK，et al. Global liver disease burdens and research trends：Analysis from a Chinese perspective [J]. J Hepatol，2019，71（1）：212-221.
[2] Revill PA，Chisari FV，Block JM，et al. A global scientific strategy to cure hepatitis B [J]. Lancet Gastroenterol Hepatol，2019，4（7）：545-558.
[3] Jian ZW，Wu XW. Effect of Nucleos（t）ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma [J]. Dig Dis Sci，2019，64（8）：2187-2198.
[4] Wu J，Jia L，Li YY，et al. Study on characteristics and prognosis of organ failure in patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. Zhonghua Gan Zang Bing Za Zhi，2018，26（10）：737-743.
[5] 中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2015年版）[J].实用肝脏病杂志，2016，19（3）：389-400.
[6] 胡德荣.肝硬化分类诊断有新标准[N].健康报，2015-09-11（002）.
[7] Feng X，Shi XF. Research progress in prognostic factors of hepatitis B virus-associated end-stage liver disease [J].Zhonghua Gan Zang Bing Za Zhi，2018，26（8）：626-629.
[8] Yang L，Ye S，Zhao X，et al. Molecular Characterization of HBV DNA Integration in Patients with Hepatitis and Hepatocellular Carcinoma [J]. J Cancer，2018，9（18）：3225-3235.
[9] 段少琼，周天彤，刘丽，等.双歧杆菌三联活菌胶囊治疗慢性乙型肝炎合并肝硬化疗效及对肝功能、肝纤维化的影响[J].疑难病杂志，2018，17（4）：362-365.
[10] Zou Z，Xu D，Li B，et al. Compartmentalization and its implication for peripheral immunologically-competent cells to the liver in patients with HBV-related acute-on-chronic liver failure [J]. Hepatol Res，2009，39（12）：1198-1207.
[11] 贾杰，吴彪.肝硬化的发病机制及诊断[J].肝博士，2010（2）：10-11.
[12] 李萍，王丽，胡蓉，等.血清纤维化标志物和肝功能指标在慢性乙型肝炎患者肝纤维化诊断中的价值[J].疑难病杂志，2017，16（6）：575-578，583.
[13] 李正鑫，陈洋溢，赵志敏，等.基于肝脏病理学对慢性乙型肝炎肝硬化患者FibroTouch测量值的影响因素分析[J].临床肝胆病杂志，2019，35（2）：338-344.
[14] 田玉梅，赵静，陈盼，等.医用臭氧联合甘草酸二胺胶囊治疗慢性乙型肝炎肝纤维化疗效及对肝功能的影响[J].疑难病杂志，2018，17（6）：572-575.
[15] Meng N，Gao X，Yan W，et al. Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses [J]. J Huazhong Univ Sci Technolog Med Sci，2015，35（2）：230-234.
[16] 袁灵，曾白梅，林世德.慢性乙型肝炎患者核苷（酸）类似物治疗后相关肌损伤的发病机制及诊疗进展[J].临床肝胆病杂志，2019，35（3）：627-630.
[17] 叶冬梅.柔肝化纤颗粒改善肝硬化Child-Pugh A、B级患者肝功能、凝血功能的临床研究[D].南宁：广西中医药大学，2016.
[18] 刘晓辉，余口，邓仰刚，等.干扰素联合阿德福韦酯对慢性乙肝患者HBV-DNA定量的影响[J].当代医学，2017， 23（25）：15-17.
[19] 焦娇，郭意男，章国君，等.乙肝肝硬化进展原发性肝癌的危险因素研究[J].预防医学，2019，31（4）：363-366，370.
[20] 中华中医药学会肝胆病专业委员会，中国民族医药学会肝病专业委员会.慢性乙型肝炎中医诊疗指南（2018年版）[J].临床肝胆病杂志，2018，34（12）：97-102.
[21] 陈力.恩替卡韦联合阿德福韦酯治疗HBeAg阴性慢性乙型肝炎患者的临床分析[J].当代医学，2018，24（3）：22-24.
[22] 赵海燕，杨东，洪伟，等.慢性乙型肝炎、乙肝肝硬化患者中HBV-DNA水平、HBV-M、淋巴细胞亚型特点分析[J].广东医学，2019，40（3）：432-435.
[23] 郭耿龙.恩替卡韦联合阿德福韦酯治疗双重耐药慢性乙型肝炎的疗效观察[J].中国实用医药，2018，13（23）：109-111.
[24] 朱豫萌，张国强.阿德福韦酯联合拉米夫定与恩替卡韦单药治疗乙型肝炎肝硬化的疗效研究[J].实用医技杂志，2019，26（2）：183-185.
[25] 陈利，肖兰春.阿德福韦酯治疗慢性乙型肝炎的不良反应分析[J].中外医疗，2017，36（13）：121-123.
[26] Wang ZC，Yang S，Huang JJ，et al. Effect of Rougan Huaqian granules combined with human mesenchymal stem cell transplantation on liver fibrosis in cirrhosis rats [J]. Asian Pac J Trop Med，2014，7（7）：576-581.